Stem cell-derived clade F AAVs mediate high-efficiency homologous recombination-based genome editing

Authors:

Abstract
The precise correction of genetic mutations at the nucleotide level is an attractive permanent therapeutic strategy for human disease. However, despite significant progress, challenges to efficient and accurate genome editing persist. Here, we report a genome editing platform based upon a class of hematopoietic stem cell (HSC)-derived clade F adeno-associated virus (AAV), which does not require prior nuclease-mediated DNA breaks and functions exclusively through BRCA2-dependent homologous recombination. Genome editing is guided by complementary homology arms and is highly accurate and seamless, with no evidence of on-target mutations, including insertion/deletions or inclusion of AAV inverted terminal repeats. Efficient genome editing was demonstrated at different loci within the human genome, including a safe harbor locus, AAVS1, and the therapeutically relevant IL2RG gene, and at the murine Rosa26 locus. HSC-derived AAV vector (AAVHSC)-mediated genome editing was robust in primary human cells, including CD34+ cells, adult liver, hepatic endothelial cells, and myocytes. Importantly, high-efficiency gene editing was achieved in vivo upon a single i.v. injection of AAVHSC editing vectors in mice. Thus, clade F AAV-mediated genome editing represents a promising, highly efficient, precise, single-component approach that enables the development of therapeutic in vivo genome editing for the treatment of a multitude of human gene-based diseases. Significance Precise genomic correction of pathogenic mutations is an attractive therapeutic strategy. Here, we show that a unique class of stem cell-derived nonpathogenic virus, hematopoietic stem cell-derived adeno-associated virus vector (AAVHSC), mediates precise genome editing at unprecedented efficiencies in primary human cells, including postmitotic cells, and in vivo. Unlike the majority of current editing platforms, genome editing by AAVHSC is uniquely based on homologous recombination (HR), requiring no exogenous nucleases. AAVHSC-mediated editing is seamless, with no evidence of on-target insertion/deletion mutations common to nuclease-based platforms. Efficient in vivo editing was achieved by i.v. injection of AAVHSC editing vectors. The combination of efficient and precise HR-based genome editing coupled with the superior in vivo transduction properties of AAV facilitates progress toward in vivo therapeutic gene editing.
Funding Information
  • HHS | NIH | National Heart, Lung, and Blood Institute (HL087285)
  • HHS | NIH | National Cancer Institute (P30CA033572)

This publication has 78 references indexed in Scilit: